General PITTER project information

Last updated: 2023-04-04 09:52

Project name

Predictive Tests for a Therapeutic Response

Project abbreviation


Project code


Primary organization that oversees implementation of project

  • National Institute for Health and Disability Insurance (RIZIV-INAMI)

Partner organization participating in project

  • Sciensano
  • Belgian Cancer Registry

Organization that commissioned this project

  • National Institute for Health and Disability Insurance (RIZIV-INAMI)

Organization providing monetary or material support

  • National Institute for Health and Disability Insurance (RIZIV-INAMI)

Brief project description

For a number of diseases/disorders, personalized treatment today offers a great added value compared to classical, empirical therapy. Thanks to molecular diagnostics, specific aberrations can be detected, which are an indication for a correct diagnosis and prognosis and the successful use of a corresponding drug in order to target the disease.

Currently the reimbursement of personalized medicines is not coupled with that of the accompanying biomarker which often leads to a delay in reimbursement of the predictive tests as compared to the personalized medicine. To better align reimbursement of the medicine and the predictive test, a reimbursement procedure will be created that will allow a monthly update of reimbursed personalized medicines and their corresponding predictive test, and as such will be flexible enough to adjust for the rapid evolving field of personalized medicine.

Regulatory framework of this project

Consult the regulatory framework information published on the pages.